Back to top Open menu arrow
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. Department of Psychiatry and Psychology, Mayo Clinic Depression Center, Mayo Clinic College of Medicine, Rochester, Minnesota
  2. Corresponding author: Balwinder Singh, MD, Mayo Clinic, 200 First St SW, Rochester, MN 55905 ([email protected]).
  3. Department of Psychiatry and Psychology, Mayo Clinic Depression Center, Mayo Clinic College of Medicine, Rochester, Minnesota
  4. Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota
  5. Department of Psychiatry and Psychology, Mayo Clinic Depression Center, Mayo Clinic College of Medicine, Rochester, Minnesota
  6. Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota
  7. Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota
  8. Department of Psychiatry and Psychology, Mayo Clinic Depression Center, Mayo Clinic College of Medicine, Rochester, Minnesota
  9. Department of Psychiatry and Psychology, Mayo Clinic Depression Center, Mayo Clinic College of Medicine, Rochester, Minnesota
  1. Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75(4):336–346. PubMed CrossRef
  2. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000;61(suppl 6):4–6. PubMed
  3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. PubMed CrossRef
  4. Johnston KM, Powell LC, Anderson IM, et al. The burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. J Affect Disord. 2019;242:195–210. PubMed CrossRef
  5. Singh B, Port JD, Voort JLV, et al. A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration. Psychiatry Res. 2021;301:113953. PubMed CrossRef
  6. Singh B, Port JD, Pazdernik V, et al. Racemic ketamine treatment attenuates anterior cingulate cortex GABA deficits among remitters in treatment-resistant depression: a pilot study. Psychiatry Res Neuroimaging. 2022;320:111432. PubMed CrossRef
  7. Vande Voort JL, Morgan RJ, Kung S, et al. Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord. 2016;206:300–304. PubMed CrossRef
  8. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864. PubMed CrossRef
  9. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67(8):793–802. PubMed CrossRef
  10. A new indication for esketamine nasal spray (Spravato). Med Lett Drugs Ther. 2020;62(1607):151. PubMed
  11. Nuñez NA, Joseph B, Pahwa M, et al. An update on the efficacy and tolerability of oral ketamine for major depression: a systematic review and meta-analysis. Psychopharmacol Bull. 2020;50(4):137–163. PubMed
  12. Joseph B, Parsaik AK, Ahmed AT, et al. A systematic review on the efficacy of intravenous racemic ketamine for bipolar depression. J Clin Psychopharmacol. 2021;41(1):71–75. PubMed CrossRef
  13. Singh B, Vande Voort JL, Frye MA, et al. Can ketamine be a safe option for treatment-resistant bipolar depression? Expert Opin Drug Saf. 2022;21(6):717–720. PubMed CrossRef
  14. Phillips JL, Norris S, Talbot J, et al. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry. 2019;176(5):401–409. PubMed CrossRef
  15. O’Brien B, Wilkinson ST, Mathew SJ. An update on community ketamine practices. Am J Psychiatry. 2022;179(5):393–394. PubMed CrossRef
  16. Bahji A, Vazquez GH, Zarate CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021;278:542–555. PubMed CrossRef
  17. Singh B, Bobo WV, Rasmussen KG, et al. The association between body mass index and remission rates in patients with treatment-resistant depression who received intravenous ketamine. J Clin Psychiatry. 2019;80(6):19l12852. PubMed CrossRef
  18. Rasmussen KG, Lineberry TW, Galardy CW, et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol. 2013;27(5):444–450. PubMed CrossRef
  19. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–583. PubMed CrossRef
  20. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–389. PubMed CrossRef
  21. Carmody TJ, Rush AJ, Bernstein IH, et al. Making clinicians lives easier: guidance on use of the QIDS self-report in place of the MADRS. J Affect Disord. 2006;95(1–3):115–118. PubMed CrossRef
  22. McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383–399. PubMed CrossRef
  23. Quibell R, Fallon M, Mihalyo M, et al. Ketamine. J Pain Symptom Manage. 2015;50(2):268–278. PubMed CrossRef
  24. Bremner JD, Krystal JH, Putnam FW, et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 1998;11(1):125–136. PubMed CrossRef
  25. Wilkinson ST, Toprak M, Turner MS, et al. A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. Am J Psychiatry. 2017;174(7):695–696. PubMed CrossRef
  26. Riva-Posse P, Reiff CM, Edwards JA, et al. Blood pressure safety of subanesthetic ketamine for depression: a report on 684 infusions. J Affect Disord. 2018;236:291–297. PubMed CrossRef
  27. Yang C, Shirayama Y, Zhang JC, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5(9):e632. PubMed CrossRef
  28. Wei Y, Chang L, Hashimoto K. Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor. Mol Psychiatry. 2022;27(1):559–573. PubMed CrossRef
  29. Leal GC, Bandeira ID, Correia-Melo FS, et al. Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci. 2021;271(3):577–582. PubMed CrossRef
  30. Nikayin S, Rhee TG, Cunningham ME, et al. Evaluation of the trajectory of depression severity with ketamine and esketamine treatment in a clinical setting. JAMA Psychiatry. 2022;79(7):736–738. PubMed CrossRef
  31. Javorcikova Z, Dangoisse M, Nikis S, et al. The place of S-ketamine in fibromyalgia treatment (ESKEFIB): study protocol for a prospective, single-center, double-blind, randomized, parallel-group, dose-escalation controlled trial. Trials. 2021;22(1):853. PubMed CrossRef
  32. Pastrak M, Abd-Elsayed A, Ma F, et al. Systematic review of the use of intravenous ketamine for fibromyalgia. Ochsner J. 2021;21(4):387–394. PubMed CrossRef
  33. Drevets WC, Popova V, Daly EJ, et al. Comments to Drs. Bahji, Vazquez, and Zarate. J Affect Disord. 2021;283:262–264. PubMed CrossRef
  34. McIntyre RS, Carvalho IP, Lui LMW, et al. The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis. J Affect Disord. 2020;276:576–584. PubMed CrossRef
  35. Correia-Melo FS, Leal GC, Vieira F, et al. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disord. 2020;264:527–534. PubMed CrossRef
  36. Frye MA, Blier P, Tye SJ. Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. J Clin Psychopharmacol. 2015;35(3):334–336. PubMed CrossRef
  37. Price RB, Kissel N, Baumeister A, et al. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators [published online ahead of print September 7, 2022]. Mol Psychiatry. 2022. PubMed CrossRef
  38. Singh B, Vande Voort JL, Kung S. Ketamine for treatment-resistant bipolar depression-need for more data! Bipolar Disord. 2021;23(7):728–729. PubMed CrossRef
Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Save Save

Share Share

Cite Cite

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe now